Research programme: pain therapeutics - Eli Lilly/RaQualia Pharma

Latest Information Update: 02 Jul 2014

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Eli Lilly; RaQualia Pharma
Class Analgesics
Mechanism of Action Ion channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Pain

Most Recent Events

27 Jun 2014 RaQualia Pharma and Eli Lilly conclude the term of their research agreement for the development of pain therapeutics
27 Jun 2014 Discontinued for Pain in USA (unspecified route)
19 Jul 2013 RaQualia Pharma and Eli Lilly agree to extend their research agreement for the development of pain therapeutics

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.